The human medicines committee of the European Medicines Agency (EMA) will consider granting a permit for the use of the Covid-19 vaccine developed by BioNTech and Pfizer in the EU on December 21. This was reported by the press service of the agency.
"An exceptional meeting of the CHMP has now been scheduled for December 21 to conclude if possible," the statement said.
At the same time, it was noted that the meeting planned for December 29 would be maintained if needed.
As we reported earlier, the U.S. Food and Drug Administration (FDA) stated that Moderna Inc. coronavirus vaccine was safe and effective.
According to the administration's report, there are no specific safety concerns and serious adverse reactions are rare. The most common side effects included fever, headaches, and muscle and joint pain. The vaccine efficacy is 94.1%.
The use of the vaccine in the USA might be approved in the next two days. After the approval, the supply of the vaccine might start within the first 24 hours.